Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect.
Researchers at the University of Pennsylvania School of Medicine found that despite strong scientific evidence in the laboratory demonstrating the ability of curcumin (the active ingredient in the spice turmeric) to inhibit a critical pathway of psoriasis, the positive response in patients was so low that scientists suggest the placebo effect or the disease’s natural remission might be the reason. The study was published in the Journal of the American Academy of Dermatology.
“Alternative and complementary websites and newspapers publish anecdotal reports that the Indian spice has been successfully used to treat psoriasis,” says Joel M. Gelfand, MD, MSCE, of The University of Pennsylvania School of Medicine. “However, spontaneous improvements in psoriasis are common, and based on our study, until larger, placebo-controlled trials are conducted, oral curcumin should not be recommended for the treatment of psoriasis given lack of proven efficacy.”
But the researchers do not discount entirely the potential of curmumin as a treatment for psoriasis.
They recognize that current traditional pharmacologic approaches in the treatment of psoriasis are costly and have their limitations, including the risk of infections and possibly malignancies with long-term use resulting in many patients with the disease unable to achieve effective long-term control. Turning to complementary and alternative therapies is understandable, they say. In fact, of the estimated 7 million diagnosed with psoriasis, it is estimated that 51% use complementary and alternative medicine therapies to treat their skin.
The excellent responses that were observed in two of the 12 patients in the study suggest that curcumin may have promise for a small subset of patients with psoriasis. Large, placebo-controlled trials are necessary to definitively prove or disprove oral curcumin as a potential therapeutic agent for psoriasis. “What is needed is scientific data to assess the safety and efficacy of these treatments so that we may more rationally inform patients of their treatment options,” says Gelfand.
Source: University of Pennsylvania
Related stories:
FDA orders stronger warnings for 4 arthritis drugs
(AP) -- The Food and Drug Administration ordered stronger warnings Thursday on four medications widely used to treat rheumatoid arthritis and other serious illnesses, saying they can raise the risk of possibly fatal fungal infections.
Could arthritis wonder drugs provide clues for all disease?
Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis – a leading cause of heart disease – says the researcher who jointly invented and developed them.
New research reveals ultraviolet light therapy is as beneficial for darker skin as lighter skin
An analysis of more than 100 patients has confirmed for the first time that darker-skinned patients benefit as those with lighter skin when given light therapy for morphea and related diseases, UT Southwestern Medical Center researchers show.
Complexity of Crohn's disease revealed as 'gene' count tops 30
New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty. The research, published today in the journal
Nature Genetics, has identified a number of potential new targets for drug development as well as providing surprising new links between the condition and other common diseases including asthma.
Scientist study bacterial communities inside us to better understand health and disease
The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity. Despite their vital imporance in human health and disease, these communities residing within us remain largely unstudied and a concerted research effort needs to be made to better understand them, say researchers today at the 108th General Meeting of the American Society for Microbiology in Boston.
Researchers uncover new genetic links to psoriasis
In the first comprehensive study of the genetic basis of psoriasis, researchers at Washington University School of Medicine in St. Louis have discovered seven new sites of common DNA variation that increase the risk of the troublesome skin condition. They also found that variations in one genetic region link psoriasis and a related joint disorder, psoriatic arthritis, to four autoimmune diseases: type 1 diabetes, Grave's disease, celiac disease and rheumatoid arthritis. The study's results appear April 4 in the open-access journal
PLoS Genetics.
Psoriasis lesions loaded with newly discovered immune cell
A new study of psoriasis patients shows that a recently discovered immune cell, called Th17, appears to be a key player in the disease and occurs in far higher concentrations in their skin than occurs in skin of healthy individuals.
New drug lets kids feel good in their skin
Maria Anichini, a 20-year-old junior at Columbia College, zipped up a fetching black lace cocktail dress with spaghetti straps to go out with friends the other night. Nothing out of the ordinary for most young women, but for Anichini it was a remarkable moment. She didn't have to hide her arms under a shawl or camouflage her legs under nylons. Her skin was smooth and completely clear of the itchy and red scaly patches of psoriasis that used to cover nearly every inch of her body.